Yin Hao, Zhang Jinping, Zhao Wei, Zheng Meimei, Song Yun, Sun Lili, Zhang Jun, Han Ju
Department of Neurology, The First Affiliated Hospital of Shandong First Medical University, Jinan, China.
Front Neurol. 2022 Feb 11;13:840865. doi: 10.3389/fneur.2022.840865. eCollection 2022.
Studies on the recanalization for occlusion of the internal carotid artery terminus are scattered. Recently, drug-coated balloon (DCB) has been increasingly applied in the intracranial artery occlusion and achieved encouraging results. However, there seems no convincing data for the nonacute symptomatic internal carotid artery terminus occlusion (sICATO).
To assess the feasibility and effectiveness (safety) of DCB for patients with nonacute sICATO refractory to medical therapy.
This study included 30 patients with nonacute sICATO treated with DCBs and/or remedial stenting. The rate of successful recanalization, periprocedural complications, and clinical and vascular imaging follow-up outcomes were retrospectively analyzed.
Drug-coated balloon (DCB) dilatation of nonacute sICATO gives a 100% rate of successful recanalization, with a low complication rate (10.00%), good clinical outcomes (86.20%), low restenosis/reocclusion rate (3.45%), and one asymptomatic ipsilateral infarction (3.45%).
Drug-coated balloon dilation seems to be the promising treatment option for nonacute sICATO considering its safety and feasibility.
关于颈内动脉终末段闭塞再通的研究较为分散。近年来，药物涂层球囊（DCB）在颅内动脉闭塞治疗中的应用日益广泛，并取得了令人鼓舞的效果。然而，对于非急性症状性颈内动脉终末段闭塞（sICATO），似乎尚无令人信服的数据。
评估药物涂层球囊治疗药物治疗无效的非急性sICATO患者的可行性和有效性（安全性）。
本研究纳入了30例接受药物涂层球囊和/或补救性支架治疗的非急性sICATO患者。回顾性分析再通成功率、围手术期并发症以及临床和血管影像学随访结果。
药物涂层球囊扩张治疗非急性sICATO的再通成功率为100%，并发症发生率低（10.00%），临床效果良好（86.20%），再狭窄/再闭塞率低（3.45%），有1例无症状性同侧梗死（3.45%）。
考虑到药物涂层球囊扩张的安全性和可行性，其似乎是治疗非急性sICATO的有前景的治疗选择。
